Correspondence 0001193125-25-118794 from Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Date: May 13, 2025 · CIK: 0001610618 · Accession: 0001193125-25-118794
AI Filing Summary & Sentiment
File numbers found in text: 333-287104
Letter
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
May 13,
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Doris Stacey Gama
Re: Cidara Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-3
Filed: May 8, 2025
File No. 333-287104
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3, to become effective at 4:00 p.m. Eastern Time on May 15, 2025 or as soon thereafter as is practicable.
If you have any questions regarding this request, please contact Charles J. Bair of Cooley LLP at (858) 550-6142.
Very truly yours,
CIDARA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 May 13, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Cidara Therapeutics, Inc. (the “Company”) Registration Statement on Form S-3 Filed: May 8, 2025 File No. 333-287104 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3, to become effective at 4:00 p.m. Eastern Time on May 15, 2025 or as soon thereafter as is practicable. If you have any questions regarding this request, please contact Charles J. Bair of Cooley LLP at (858) 550-6142. Very truly yours, CIDARA THERAPEUTICS, INC. /s/ Jeffrey Stein, Ph.D. Jeffrey Stein, Ph.D. President and Chief Executive Officer